Literature DB >> 17031685

Severe infectious complications in a patient treated with rituximab for idiopathic thrombocytopenic purpura.

Luana Fianchi, Elena Rossi, Rita Murri, Valerio De Stefano, Livio Pagano, Giuseppe Leone.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17031685     DOI: 10.1007/s00277-006-0206-1

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  5 in total

Review 1.  Does rituximab increase the incidence of infectious complications? A narrative review.

Authors:  Theodoros Kelesidis; George Daikos; Dimitrios Boumpas; Sotirios Tsiodras
Journal:  Int J Infect Dis       Date:  2010-11-11       Impact factor: 3.623

Review 2.  Chinese guidelines for treatment of adult primary immune thrombocytopenia.

Authors:  Xin-Guang Liu; Xiao-Chuan Bai; Fang-Ping Chen; Yun-Feng Cheng; Ke-Sheng Dai; Mei-Yun Fang; Jian-Ming Feng; Yu-Ping Gong; Tao Guo; Xin-Hong Guo; Yue Han; Luo-Jia Hong; Yu Hu; Bao-Lai Hua; Rui-Bing Huang; Yan Li; Jun Peng; Mi-Mi Shu; Jing Sun; Pei-Yan Sun; Yu-Qian Sun; Chun-Sen Wang; Shu-Jie Wang; Xiao-Min Wang; Cong-Ming Wu; Wen-Man Wu; Zhen-Yu Yan; Feng-E Yang; Lin-Hua Yang; Ren-Chi Yang; Tong-Hua Yang; Xu Ye; Guang-Sen Zhang; Lei Zhang; Chang-Cheng Zheng; Hu Zhou; Min Zhou; Rong-Fu Zhou; Ze-Ping Zhou; Hong-Li Zhu; Tie-Nan Zhu; Ming Hou
Journal:  Int J Hematol       Date:  2018-04-04       Impact factor: 2.490

3.  Eltrombopag, a thrombopoietin- receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile.

Authors:  Gregory Cheng
Journal:  Ther Adv Hematol       Date:  2012-06

4.  Corticosteroid Risk Function of Severe Infection in Primary Immune Thrombocytopenia Adults. A Nationwide Nested Case-Control Study.

Authors:  Guillaume Moulis; Aurore Palmaro; Laurent Sailler; Maryse Lapeyre-Mestre
Journal:  PLoS One       Date:  2015-11-11       Impact factor: 3.240

Review 5.  Bacterial Infections Following Splenectomy for Malignant and Nonmalignant Hematologic Diseases.

Authors:  Giuseppe Leone; Eligio Pizzigallo
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-10-13       Impact factor: 2.576

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.